



# BB Adamant Global Healthcare Index Fund Class T

Factsheet October 2015

## > Performance CHF

Since	1m	YTD	1yr	3yrs	5yrs	Incept.
Fund	5.3	3.4	6.2	67.4	n.a.	99.7
Adamant Index <sup>1)</sup>	5.7	5.2	8.3	77.1	n.a.	118.7
Relative Performance	-0.4	-1.8	-2.1	-9.7	n.a.	-19.0

Annualised <sup>2)</sup>	3yrs	5yrs	Incept.
Fund	18.7	n.a.	18.7
Adamant Index <sup>1)</sup>	21.0	n.a.	21.4


1) No costs were taken into account for the calculation of the index.

2) Annualised performance will be calculated only one year after launch.

## > Fund Description

The BB Adamant Global Healthcare Index fund essentially replicates the performance of the Adamant Index (total return). The fund invests directly in the 40 companies from the healthcare sector contained in the Adamant Index. The four regions of Western Europe, North America, Japan / Australia and Emerging Markets are represented with 10 stocks each.

## > Indexed Performance CHF



Since fund inception or at the longest for the last five years

## > Index Facts

Name	Adamant Healthcare Index Also known as "Adamant Index"
Index Advisor	Bellevue Asset Management AG
Index calculation	Standard & Poor's
Index Inception Date	20 April 2007
Bloomberg	ADAMGHCT Index

## > Historical Performance Adamant Index vs. MSCI World Health Care and MSCI World in CHF

Seit	1m	YTD	1yr	3yrs	Incept.
Adamant Index <sup>1)</sup>	5.7	5.2	8.3	77.1	141.2
MSCI World Health Care NR	7.0	4.9	8.9	82.2	65.0
MSCI World NR	8.9	0.6	4.2	47.2	5.3

1) No costs were taken into account for the calculation of the index.




> Fund Facts

Swiss Sec. No.		13 759 665
ISIN		CH0137596653
Bloomberg		ADGHCIT
Fund Currency		CHF
Additional Trading Currency		USD
Minimum Investment	CHF	1 Anteil
Net Asset Value	CHF	1'997.19
Subfund Size Class T	Mio. CHF	5.38
Total Fund Size	Mio. CHF	149.69
Shares Outstanding Class T	thousand pieces	2.70
Fund Inception Date		19 October 2011
Dividend Payment		Reinvesting
52-Week-High		2'281.92
52-Week-Low		1'696.78
TER p.a. (excl. Performance Fee)		0.91%
Performance Fee		none
Benchmark	Adamant Global Healthcare Index	
Fund Manager	Bellevue Asset Management AG	
Custodian Bank	Zürcher Kantonalbank	
Fund Management Company	Swisscanto Fondsleitung AG	

> 10 Largest Positions

Biogen Idec	3.7%
Gilead Sciences	3.7%
Cardinal Health	3.6%
Becton Dickinson	3.6%
Celgene	3.6%
Centene	3.4%
Ligand Pharmaceuticals	3.4%
Illumina	3.4%
Lannett	3.2%
Sinopharm	3.0%
Total Exposure	99.8%

> Sector Allocation



The fund has been approved in Switzerland by the supervisory authority, the Swiss Financial Market Authority (FINMA).


> Index Description

The Adamant Index is made up of 40 listed healthcare companies. The index contains ten stocks from each of the four regions Western Europe, North America, Japan/Australia and Emerging Markets.

Stocks are selected on the basis of four qualitative and four quantitative parameters. Relevant criteria include the quality of management and the product pipeline as well as key financial data, revenue growth and operating margin. Rebalancing is done every April 20 and October 20.

The index is calculated independently by Standard & Poor's, on the equity securities selected by Bellevue.

> Currency Allocation



> Risk Figures

	3 years Annualised	5 years Annualised
Volatility		
- Fund	15.1%	n.a.
- Benchmark	15.1%	n.a.
Sharpe Ratio	n.a.	n.a.

The Adamant Global Healthcare Index (the "Index") is the exclusive property of Bellevue Asset Management AG, which has contracted with Standard & Poor's Financial Services LLC ("S&P") to maintain and calculate the Index. Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC. "Calculated by S&P Custom Indices" and its related stylized mark(s) are service marks of Standard & Poor's Financial Services LLC and have been licensed for use by [Licensee]. S&P and its affiliates shall have no liability for any errors or omissions in calculating the Index.

The Royal Bank of Scotland N.V. or any of its affiliates ("RBS") is not the issuer of this financial instrument and does not give any express or implied warranty or representation, neither regarding the results deriving from the use of the [Adamant Global Healthcare Index] (the "Index") nor regarding the level of the Index at any point in time or on a certain date nor in any other respect. RBS was the index sponsor of the RBS / Adamant Healthcare Momentum Index up to and including 9 November 2011 but the performance of the RBS / Adamant Healthcare Momentum Index is in no way indicative of the future performance of the Index.

The Index is not sponsored, endorsed, sold or promoted by RBS or any other member of The Royal Bank of Scotland Group. Neither RBS nor any other member of The Royal Bank of Scotland Group makes any representation or warranty, express or implied, to any member of the public regarding the advisability of investing in financial instruments linked to the Index. Neither RBS nor any other member of The Royal Bank of Scotland Group is responsible for or has participated in the determination of the composition or the calculation of index levels or prices of the Index or the sale of any financial instrument referencing the Index. Neither RBS nor any other member of The Royal Bank of Scotland Group has any obligation or liability in connection with the composition, administration or marketing of the Index.

This Publication is for information purposes only and does not explicitly target any person who by domicile or nationality is prohibited to receive such information according to applicable law. Investors are advised that past performance is not an indicator of current or future performance and that the performance data do not take account of commission and expenses charged on the issue and redemption of units. The BB Adamant funds are investment funds under Swiss law in the "Other funds for traditional investments" category and have been established under the Swiss Collective Investment Schemes Act. The Fund's prospectus respectively key investor information, regulations and annual report may be obtained free of charge from the Fund Manager and the Custodian Bank. This document was produced by Zürcher Kantonalbank ("ZKB") applying highest diligence standards in good faith. ZKB does not warrant any guarantee with regard to correctness and completeness and waives any claim for losses that may occur through the use of this information. This Publication is neither an offer nor a recommendation for the purchase or sale of financial products or financial services and does not discharge the recipient from his own judgement. Particularly, ZKB recommends that the recipient, if need be by consulting professional guidance, assess the information in consideration of his personal situation with regard to legal, regulatory and tax consequences that might be invoked. The present document is not the result of the department "financial analysis" as defined in the rules of the "Directives on the Independence of Financial Research" edited by the Swiss Bankers Association, hence these rules do not apply to this document.

This document is for distribution and / or redistribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.

The enclosed document is only made available on the condition that it will be exclusively used by the recipient and must not be forwarded to other persons or reproduced either in part or in full. The units will not be placed as part of an active offer. The intended distribution of the units was therefore not reported to the financial market supervisory authority and the units are not part of a published prospectus in Austria. All enclosed information relating to the units thus neither represents part of a prospectus within the meaning of the Investment Fund Act (InvFG), information within the meaning of § 21 of the Alternative Investment Fund Managers Act (AIFMG) nor a prospectus within the meaning of the Capital Markets Act (KMG).

If Balfidor Fondsleitung AG, Adamant Funds or Zürcher Kantonalbank enter into a business or contractual relationship with a client whose registered office, permanent or temporary residence, domicile, administrative office or management is in Austria, these contractual terms and conditions arise exclusively at the client's own initiative and discretion. Investors are hereby informed that earnings, capital gains and capital gains tax on units are not currently reported by a tax representative to the Swiss Federal Ministry of Finance (BMF) nor to the Austrian OeKB. Accordingly, there may be detrimental taxation consequences. Taxation depends on the personal circumstances of the investor and may change in future.

This publication and the information contained in it must not be distributed and / or redistributed to, used or relied upon by, any person (whether individual or entity) who may be a US person under Regulation S under the US Securities Act of 1933. US persons include any US resident; any corporation, company, partnership or other entity organized under the any law of the United States; and other categories set out in Regulation S. This document does not constitute an offer to sell or a solicitation or invitation is to subscribe for or to make an offer to buy any securities, nor does it provide a basis for any contract or obligation of any kind. This document is not a prospectus within the meaning of article 652a or 1156 the Swiss Code of Obligations or Article 27 of the listing rules of SIX Swiss Exchange AG.

Copyright © 2015 Zürcher Kantonalbank. All rights reserved.